Date:

2025-04-30

Title of Paper:

Fluconazole versus mould‑active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost‑efectiveness analysis

Journal:

International Journal of Hematology

Summary:

This study evaluated the clinical and cost-efectiveness of prophylactic use of fuconazole versus mouldactive triazoles (voriconazole and posaconazole) in adult patients with acute lymphoblastic leukemia (ALL). A decision analytical model was developed with inputs from a 7-year retrospective study (2009–2016) of 103 consecutive adult patients with ALL who received antifungal prophylaxis. Information on the administration of antifungal agents, clinical outcomes, and costs were collected. One-way sensitivity analyses and probabilistic sensitivity analysis were performed. The mould-active triazoles group was associated with higher life-years (3.71 vs 3.59) and lower total costs (US$4886 vs US$5722) per patient compared with fuconazole. One-way sensitivity analyses revealed that varying all of the key variables in the model did not afect the robustness of the results. Probabilistic sensitivity analysis demonstrated that mould-active triazoles had a probability of 77.1 and 90.1% of providing a dominant and cost-efective option relative to fuconazole, respectively. Mould-active triazoles should be regarded as preferable to fuconazole as the frstline prophylactic for adult  patients with ALL accompanied by uncommon severe vinca alkaloid-induced neurotoxicity

Co-author:

Yan Wang, Yalin Dong*, Weihua Dong*

Translation or Not:

No

Date of Publication:

2017-10-12